Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Phase 1/2 Study of ORIC-114 as a Single Agent or in Combination With Chemotherapy, in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

NCT05315700 is registered in ClinicalTrials.gov with ORIC Pharmaceuticals as lead sponsor.

NCT NCT05315700
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05315700 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Phase 1/2 Study of ORIC-114 as a Single Agent or in Combination With Chemotherapy, in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
Lead sponsor
ORIC Pharmaceuticals
Phase
Phase 1/2
Overall status
Recruiting
Start date
March 10, 2022
Completion date
September 30, 2027
Enrollment
350 (estimated)
Sites
42

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumors